Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.705
−$0.025 · -0.44%
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Regular session
$5.705
−$0.025 · -0.44%
Regular session · ET · Market data may be delayed.
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Day range
Current $5.705
52-week range
Current $5.705
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
73
Undervalued
Sentiment
56
Mixed
Risk
52
Elevated Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Day range
Current $5.705
52-week range
Current $5.705
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 33.48M USD | 2.64M USD | 2.76M USD | 3.53M USD | −782K USD |
| Cost of goods sold | 190K USD | 204K USD | 186K USD | 322K USD | 199K USD |
| Gross profit | 33.29M USD | 2.43M USD | 2.57M USD | 3.21M USD | −981K USD |
| Research and development | 58.19M USD | 42.8M USD | 33.82M USD | 21.95M USD | 12.89M USD |
| Selling, general, and administrative | 26.91M USD | 23.93M USD | 20.26M USD | 13.92M USD | 7.93M USD |
| Operating expenses | 85.1M USD | 66.74M USD | 54.08M USD | 35.87M USD | 20.82M USD |
| Interest income | — | 3.36M USD | 3.85M USD | 50K USD | — |
| Interest expense | 1.15M USD | — | — | — | 927K USD |
| Depreciation and amortization | 327K USD | 308K USD | 287K USD | 222K USD | 181K USD |
| Operating income | −51.81M USD | −64.3M USD | −51.51M USD | −32.66M USD | −21.8M USD |
| Net income | −52.7M USD | −61.02M USD | −49.12M USD | −33.61M USD | −23.01M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.41M0.00%2.3T USD0.03%$381.2+0.43%
iShares Russell 2000 ETFIWM5.75M0.01%77.7B USD0.19%$278.36+0.28%
Vanguard Extended Market ETFVXF2.51M0.00%95.4B USD0.05%$234.3+0.50%
iShares Russell 2000 Growth ETFIWO2.14M0.02%14.04B USD0.24%$355.51+0.58%
Schwab U.S. Small-Cap ETFSCHA1.31M0.01%21.73B USD0.03%$32.7499+0.28%
Simplify Propel Opportunities ETFSURI1.26M1.68%74.84M USD2.82%$17.08360.00%
Vanguard Russell 2000 ETFVTWO1.16M0.01%18B USD0.06%$112.45+0.31%
iShares Micro-Cap ETFIWC714.54K0.05%1.32B USD0.60%$182.8+0.00%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHASimplify Propel Opportunities ETFSURIVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
